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Abstract
Extensive studies over the last 30 years have demonstrated that vascular smooth muscle cell
(SMC) differentiation and phenotypic modulation is controlled by a dynamic array of
environmental cues. The identification of the signaling mechanisms by which these environmental
cues regulate SMC phenotype has been more difficult because of our incomplete knowledge of the
transcription mechanisms that regulate SMC-specific gene expression. However, recent advances
in this area have provided significant insight, and the goal of this review is to summarize the
signaling mechanisms by which extrinsic cues control SMC differentiation.
Introduction
Smooth muscle cells (SMC) provide structural support to the vasculature and control blood
pressure and blood flow through highly regulated contractile mechanisms. Differentiated
SMC express a variety of SMC-specific contractile and contractile-associated proteins that
contribute to these functions including SM myosin heavy chain (SM MHC), SM22,
calponin, and SM α-actin. Importantly, unlike cardiac and skeletal muscle cells, SMC retain
significant plasticity even in adult animals. Thus, in response to vessel injury, SMC undergo
phenotypic modulation, a process characterized by decreased SMC differentiation marker
gene expression and increased proliferatiion, migration, and matrix synthesis. The search for
the transcription regulatory mechanisms that ultimately govern the process of SMC
differentiation has been complicated by the plasticity of this cell-type and the fact that SMC
derive from multiple precursors throughout the embryo 1. The MADS box transcription
factor, serum response factor (SRF), regulates most SMC differentiation marker genes by
binding to highly conserved CArG cis elements (CC(A/T)6GG) that are present within
nearly all of the SMC-specific promoters (see 2 for review). However, SRF cannot be
considered a master regulator of SMC differentiation because it is a ubiquitously expressed
protein that also regulates cardiac- and skeletal-muscle-specific genes expression and the
expression of a variety of early response and structural genes 3. SRF-dependent transcription
is controlled to a large extent by SRF’s interaction with additional transcription factors and
co-activators. The first SRF co-factors described were the ternary complex factors (TCFs)
like Elk-1 that regulate early response gene expression and that interact with SRF when
phosphorylated by MAP-kinase (see 4 for review). Some Nkx and Gata family members are
expressed in certain SMC sub-types (Nkx3.1, Nkx3.2, and Gata-6) and have been shown
interact with SRF to regulate SMC differentiation marker gene expression 5, 6.
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The discovery of the cardiac/SMC-selective SRF co-factor, myocardin, was a major advance
in our understanding of the transcription mechanisms that regulate SMC-specific gene
expression 7. Unlike the Nkx and Gata factors, myocardin does not contain a DNA binding
domain but powerfully transactivates cardiac and SMC-specific gene expression by
physically interacting with SRF 7. Importantly, expression of myocardin activated SMC
differentiation marker gene expression in a variety of non-SMC cells while deletion of
myocardin in the mouse resulted in embryonic lethality at E10.5 due, at least in part, to
failure of SMC differentiation within the developing dorsal aorta 8, 9. Interestingly, cardiac
development did not seem to be affected by deletion of myocardin. Additional analyses of
ES cells and chimeric mice indicated that myocardin null cells could differentiate into SMC
indicating that other transcription mechanisms could compensate for its loss at least under
some conditions 10. Two myocardin-related transcription factors, MRTF-A and MRTF-B,
have been identified that have similar transcriptional properties to myocardin 11. Although
the MRTFs are expressed more ubiquitously, both are strongly expressed in SMC and have
been shown to be required for SMC-specific gene expression in several SMC culture
models 12–14. Importantly, separate groups have shown that deletion of MRTF-Bin the
mouse resulted in defective SMC differentiation of the cardiac neural crest cells that
populate the aortic arch 15, 16. In addition, deletion of MRTF-A prevented the up-regulation
of SMC-specific gene expression that normally occurs in myoepithelial cells of the
mammary gland during lactation 17, 18. Taken together, these data indicate that the
myocardin transcription factors have unique functions that are required for SMC
differentiation marker gene expression and vascular development in vitro and in vivo.
Unfortunately, the overlapping expression patterns, functional redundancy, and potential
heterodimerization between myocardin factors has made it difficult to determine their
precise roles in SMC, especially for those aspects of SMC function that do not directly
involve specification such as the changes in SMC-specific gene expression that are known to
occur during environmental stresses.
Regulation of SRF
A critical step in the activation of SMC-specific gene expression is SRF binding to CArG
elements, and several mechanisms regulate this interaction. High SRF expression in all three
muscle cell-types likely promotes SRF binding to the relatively low affinity CArG elements
present within the muscle-specific promoters. An increase in SRF expression correlates well
with the appearance of the SMC during development 19 and can be induced by a number of
agonists such as TGF-β that are well-known stimulators of SMC differentiation 20, 21. The
transcription mechanisms that regulate SRF expression are not completely clear, but the
observation that multiple CArG elements control SRF promoter activity strongly suggests
that high SRF expression in muscle cells is facilitated by a positive feedback loop 22, 23.
Phosphorylation of Serine103 by a number of kinases increases SRF affinity for CArG
elements 24, 25, and results from Garat et al suggested that this mechanism was important for
arginine vasopressin-mediated induction of the SM α-actin promoter 26. More recent studies
from our lab and Iyer et al demonstrated that phosphorylation within SRF’s core DNA
binding domain (at S162 by PKCα and at T159 by PKA) decreased SM α-actin promoter
activity by inhibiting SRF binding 27, 28. Importantly, neither of these phosphorylation
events affected c-fos promoter activity due to the stabilizing effects of Elk-1 within the
ternary complex 27. SRF’s interaction with other transcription factors and co-factors
influences SRF binding most likely by steric alterations in SRF conformation. The
homeodomain proteins, Nkx3.1, Prx-1, and Barx2b, and the myocardin factors have been
shown to enhance SRF binding 5, 29–31 while the homeodomain-only protein (HOP)and
YY1 have been shown to inhibit SRF binding 32, 33.
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It is extremely important to note that the ability of SRF (or any other factor) to regulate
SMC differentiation absolutely requires additional mechanisms that control chromatin
structure and transcription factor access to the SMC-specific gene promoters. Consistent
with the concept of the “histone code”, binding of SRF to SMC-specific promoters
correlates strongly with positive chromatin marks (i.e. H3 acetylation, H3K4 methylation,
etc)and a number of labs including our own have shown that the myocardin factors interact
with chromatin modifiers 34–39. For a more complete discussion of this important topic we
refer the reader to other reviews 40 including the Chen review in this series.
Regulation of myocardin
Clearly, signaling mechanisms that affect myocardin levels and/or activity play a major role
in the regulation of SMC differentiation. Hendrix et al demonstrated that myocardin mRNA
expression was significantly reduced in rat carotid arteries following wire injury in a time
course that closely paralleled the down-regulation of SMC differentiation marker gene
expression in this model 41. Although the mechanism for this down regulation is not yet
clear, several studies have shown that PDGF-BB inhibits myocardin expression 14, 42 and its
release at sites of vascular injury probably contributes to this effect. Interestingly, Doi et al
failed to observe a decrease in myocardin protein expression in a rat thoracic aorta injury
model perhaps reflecting a differential response to injury governed by SMC origin 43.
Several environmental cues that enhance SMC-specific gene expression including
angiotensin II and increased calcium influx have been shown to up-regulate myocardin
expression 31, 44, 45. Callis et al demonstrated that myocardin expression in cardiomyocytes
was up-regulated by BMP-2 46, but a similar effect was not observed in SMC 47. The
transcription mechanisms that regulate myocardin expression are starting to be described.
Nkx2.5 and NFATc3were shown to bind and activate proximal myocardin promoter
fragments in cardiomyocytes, and treatment of myocardial cells with aldosterone or the β-
adrenergic agonist, isoproterenol, enhanced NFATc3 binding to the myocardin
promoter 48, 49. The relevance of these results is some what unclear given the recent
demonstration that myocardin expression in vivo is controlled by an enhancer ~25kb
upstream of myocardin’s translational start site 50. This enhancer was activated by MEF2,
and several members of the Foxo and TEAD transcription factor families, warranting further
studies on the expression and control of these factors in SMC.
The myocardin transactivation domain can be phosphorylated by GSKβ and ERK resulting
in decreased SMC differentiation marker gene expression 51–53, and these modifications
probably interfere with the transactivation domain’s ability to interact with other cell-
selective and/or general transcription factors. Of interest, myocardin has been shown to
interact with the estrogen receptor co-activator, SRC3, to enhance SMC-specific expression
in human aortic SMC 54. Somewhat surprisingly, treatment of SMC with estrogen had little
effect on this mechanism suggesting that the protective effects of estrogen on SMC
phenotypic modulation involves additional signals 55. Tang et al demonstrated that NFkB
physically interacts with myocardin to inhibit its activity 56. This important observation may
explain the down regulation of SMC differentiation marker gene expression observed under
inflammatory conditions such as those found in atherosclerosis. Liu et al demonstrated that
myocardin activity is also inhibited by its interaction with Foxo4and this mechanism has
potential implications on the regulation of SMC phenotype by agonists that stimulate
AKT 57. These authors demonstrated that IGF-1/AKT-dependent phosphorylation of Foxo4
induced its translocation from the nucleus to the cytoplasm, thus relieving Foxo4-dependent
inhibition of SMC differentiation marker gene expression. The bHLH transcription factors,
Msx1 and Msx2, interact with myocardin to inhibit SMC-specific transcription, and the up-
regulation of these factors by BMPs may be critical for the modulation of SMC phenotype
under conditions that promote vessel calcification 47. Myocardin activity is also inhibited by
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the bHLH factor, HERP1/HEY2, and the HMG protein, HMG2L1 43, 58. Both of these
factors are up-regulated in phenotypically modulated SMC and inhibit myocardin’s
interaction with SRF.
The recent demonstration that the myocardin factors are targeted for proteasome-mediated
degradation could have significant implication on the regulation of SMC differentiation. We
were the first to demonstrate that myocardin factor stability in SMC was enhanced by
proteasome inhibition and that MRTF-A was ubiquitylated 59. Xie et al have now shown
that the E3 ligase, CHIP (C-terminus of HSC70-intreacting protein), ubiquitylates
myocardin in SMC 60. Importantly, these authors demonstrated that siRNA-mediated
knockdown of CHIP significantly increased the expression of several SMC differentiation
marker genes while overexpression of CHIP in isolated aortic rings decreased SMC
contractility. Hu, et. al. identified the E3 ligase, UBR5, as a myocardin interacting protein
using a yeast-two-hybrid screen, but surprisingly, UBR5 increased myocardin stability by a
mechanism independent of its E3 ligase function 61. Myocardin and MRTF-A can also be
modified by the Small Ubiqutin-like MOdifier (SUMO), but because sumolyation activated
myocardin, but inhibited MRTF-A 62, 63 the functional significance of this modification in
regard to SMC-specific gene expression remains unknown.
Regulation of SMC differentiation by RhoA
Early studies from the Treisman lab demonstrated that SRF-dependent transcription was
regulated by the small GTPase, RhoA 64, 65. Based upon these results, we were the first to
show that RhoA activity was an important determinant of SMC differentiation marker gene
expression 66, but the mechanisms involved were still unknown. A seminal study by
Miralles et al demonstrated that RhoA-dependent actin polymerization promoted the nuclear
localization of MRTF-A and that G-actin binding to MRTF-A’s N-terminal RPEL domains
inhibited this translocation 67. MRTF-B nuclear localization is also controlled by this
mechanism, but since the myocardin RPEL domains do not bind G-actin very strongly,
myocardin is constitutively nuclear 68. Many groups have now shown that RhoA activity is
required for SMC-specific gene expression in a variety of SMC differentiation models 69–74
and for the up-regulation of SMC-specific transcription in response to many environmental
cues including thrombin, sphingosine 1-phosphate (S1P), TGF-β, calcium, BMP-2, and cell
tension 44, 72, 74–80. In several of these models the activation of SMC-specific gene
expression was accompanied by MRTF nuclear accumulation as measured by nuclear
fractionation, immunohistochemistry, or localization of GFP-tagged MRTF
variants 75, 78–80. In addition, we have shown that RhoA-dependent SMC-specific promoter
activity was inhibited by expression of a nuclear localization deficient variant of MRTF-A
that traps endogenous MRTFs in the cytoplasm 12. Since this intervention does not affect
myocardin activity or MRTF expression, these data provided direct evidence for MRTF
nuclear translocation as an important signaling mechanism in the control of SMC-specific
gene expression.
The mechanisms that regulate RhoA in SMC have not been completely described and are
likely to be complex. Like all small GTPases, RhoA activation is tightly regulated by
GTPase Activating Proteins (GAPs) that facilitate RhoA’s intrinsic GTPase activity
(inhibiting RhoA) and Guanine Exchange Factors (GEFs) that facilitate exchange of GDP
for GTP (activating RhoA) (see 81 for review). In SMC, RhoA activity is mainly regulated
by agonists such as angiotensin II (AII), thrombin, and S1P that signal through G-protein
coupled receptors (GPCRs). GPCR-dependent activation of RhoA is mediated, at least in
part, by Gα12/13-dependent activation of the RGS family of RhoGEFs (LARG,
p115RhoGEF, and PDZRhoGEF) 82 and/or Gαq/11-dependent activation of the Trio family
of RhoGEFS (Trio, Duet, and p63RhoGEF) 83, 84. SMC typically express multiple receptors
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for the same agonist and because these receptors have different G-protein coupling
properties it has been difficult to predict or determine the relative importance of these
proteins to SMC-specific transcription. Using a combination of receptor sub-type-specific
agonists for the fiveS1P receptors (S1PR1-5), we and others have demonstrated that S1PR2
is a major activator of RhoA in SMC and is required for S1P-dependent up-regulation of
SMC-specific gene expression 85, 86. Our data also suggest that theS1PR2 signals mainly
through LARG to activate RhoA in SMC 86. Interestingly, S1PR2deficient mice do not
show an overt SMC phenotype, but Shimizu et al have recently demonstrated that they are
more susceptible to injury-induced restenosis 87 suggesting that S1P signaling through this
pathway helps maintain SMC differentiation in vivo. Angiotensin II-dependent activation of
RhoA in SMC is much more complex and has been shown to be mediated byJAK2-
dependent activation of p115RhoGEF 88, inhibition of p190RhoGAP 89, up-regulation of
LARG 90, and calcium-activated phosphorylation of PDZ-RhoGEF by the tyrosine kinase,
PYK2 91.
The signaling mechanisms downstream of RhoA that control MRTF nuclear localization
involve multiple RhoA effectors that enhance actin polymerization. Rho-kinase stimulates
actin polymerization by inhibiting the disassembly of actin polymers through LIM-kinase-
dependent inhibition of cofilin 92. Pharmacologic inhibition of Rho-kinase withY-27632
significantly attenuates SMC-specific gene expression, but does not completely inhibit
it 12, 44, 75. The diaphanous-related formins (DRFs), mDia1 and mDia2, are RhoA effectors
that directly catalyze actin polymerization through a mechanism that involves profilin 93, 94,
and we have shown that both are highly expressed in SMC, and are required for SMC
differentiation marker gene expression 95. Another DRF, FHOD1 (formin homology domain
containing protein-1), is also highly expressed in SMC 96. Although FHOD1 binds Rac and
not RhoA, its activity is regulated by ROCK-dependent phosphorylation 97, and we have
shown that this signaling mechanism contributes to SMC-specific transcription 96. The
RhoA effector, protein kinase-N, was shown to up-regulate SMC-specific gene expression
by a mechanism yet to be described 77.
Taken together these data strongly suggest that RhoA-dependent regulation of MRTF
nuclear localization is an important mechanism for the regulation of SMC differentiation
marker gene expression and is facilitated in SMC by a combination of parameters including
high SRF and myocardin factor expression levels, strong GPCR-dependent activation of
RhoA, and relatively high expression of downstream RhoA effectors. Finally, it is important
to note that like SRF, RhoA also regulates cell proliferation and several studies have
demonstrate that RhoA signaling was required for the stimulation of SMC growth by AII,
thrombin, mechanical stretch, and vessel injury 98–102. However, it is also clear that SMC
growth and differentiation are not mutually exclusive and that activation of RhoA by itself is
not sufficient to stimulate SMC proliferation 75, 95, 103, 104.
Regulation of SMC differentiation by TGF-β
TGF-β is a multifunctional cytokine that regulates vascular development and maintenance
by controlling the growth, differentiation, and matrix synthesizing properties of EC, SMC,
and lymphocytes. In most cells including SMC, TGF-β signals mainly through a heteromeric
complex of two serine/threonine kinase receptors, the type IITGF-β receptor (TβRII)and the
type I receptor, ALK5 (see 105 for review). Within the ligand-induced receptor complex,
constitutively active TβRII phosphorylates ALK5 resulting in the recruitment and
phosphorylation-dependent activation of Smads 2 and 3. The activated Smads complex with
Smad4 and then translocate to the nucleus where they stimulate gene expression. The Smads
contain DNA binding motifs and have been shown to interact with DNA at a consensus
Smad binding element (GTCT). However, because Smads bind these elements with very
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low affinity it is thought that they regulate transcription in combination with additional
transcription factors and co-factors.
Extensive studies have shown that TGF-β strongly stimulates SMC differentiation marker
gene expression in a number of cell types including 10T1/2, Monc-1, mesenchymal and
embryonic stem cells, lung fibroblasts, and aortic SMC 20, 106–113. This effect requires
activation of Smad2 and/or Smad3, and several studies have demonstrated that these Smads
interact with the SMC-specific promoters at putative Smad binding elements 107, 108, 114, 115.
The effects of TGF-β are also CArG/SRF-dependent 20, and studies by Qui et al have shown
that Smad3 physically interacts with SRF to facilitate SMC-specific gene expression 114.
Interestingly, this group demonstrated that Smad3 can recruit myocardin to the SM22
promoter by a direct interaction between these transcription factors 115. Nishimura, et. al.
have shown that Smad3 also interacts with δEF1, a zinc finger- and homeodomain-
containing protein expressed in SMC 112. δEF1 was up-regulated by TGF-β, formed a
complex with SRF and Smad3 on the SM α-actin promoter and was required for the full
effects of TGF-β on SMC-specific gene expression. TGF–β also up-regulates the expression
of many proteins that have secondary effects on SMC phenotype including many matrix and
matrix remodeling proteins (see 116 for review). The discovery that the effects of TGF-β on
SMC-specific gene expression were mediated at least in part by the NADPH oxidase,
Nox4, 117–120 was particularly intriguing and supported previous reports that reactive
oxygen species regulate SMC-specific transcription 121, 122. Interestingly, reactive oxygen
species have been shown to regulate a number of critical SMC processes 123 but the precise
mechanisms involved are currently unknown.
By poorly understood mechanisms, TGF-β directly activates (within minutes) several
signaling pathways that affect SMC phenotype (see 124 for review). Activation of p38, most-
likely by TGF-β-activated kinase, was shown to required for TGF-β-induced SM α-actin
expression in fibroblasts and Pac-1 SMC 77, 125, 126. Activation of p38 also inhibits cell
cycle progression and is required for TGF-β’s ability to inhibit SMC proliferation 127. Lien
et al have demonstrated that TGF-β activates AKT in 10T1/2 cells and that this signaling
pathway was required for TGF-β’s effects on SMC-specific transcription 128. TGF-β also
activates RhoA in SMC and SMC precursors, and inhibition of RhoA signaling prevented
TGF-β-dependent SMC differentiation marker gene expression in these models 74, 77. In our
hands, TGF-β is a relatively weak and slow activator of RhoA and did not stimulate MRTF
nuclear localization in SMC at early time-points (< 2h) 12 suggesting a different mechanism
for its requirement. Interestingly, inhibition of RhoA prevented Smad2 and Smad3 nuclear
localization 74, but this potentially important mechanism will require further investigation.
Recent studies have shown that TGF-β up-regulates the expression of multiple RhoA
signaling proteins including the Rho GEFs, Net-1 and GEF-H1, and RhoB 129–131
suggesting that TGF-β’s ability to promote long-term activation of RhoA signaling may
contribute to its effects on SMC differentiation.
Notch signaling plays a dual role in the regulation of SMC differentiation
Recent studies have demonstrated that Notch signaling plays an important role in vascular
development and maintenance (see 132 for reviews). Four single-pass transmembrane Notch
receptors (Notch1–4) have been described in mammals with Notch3 most strongly expressed
in SMC. Importantly, the Notch receptors interact with ligands that are also transmembrane
proteins (Jagged1 and 2 and Delta-like1, 3, and 5) thus limiting Notch signaling to adjacent
cells. Activation of Notch by ligand binding results in proteolytic cleavage of the receptor by
γ-secretase, release of the Notch intracellular domain (NICD), and translocation of the
NICD to the nucleus where it interacts with the multifunctional transcription regulator,
RBPJ. In the absence of NICD, RBPJ binds and represses target genes by recruiting HDACs
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and other transcriptional repressors. Displacement of the repressive factors upon NICD
binding and the eventual recruitment of transcriptional activators such as MAML and
histone acetyltransferases results in activation of Notch target genes. Major gene targets of
Notch are the Hes and Hey/HERP transcription regulators.
Notch signaling has been shown to promote SMC differentiation marker gene expression,
but its effects are likely depend upon cell context. Over-expression of NICD in 10T1/2 or
human SMC cells stimulated SMC differentiation marker gene expression, and RBPJ was
shown to interact with the SM α-actin promoter by ChIP assays 133, 134. Endothelial-specific
deletion of Jagged1 resulted in embryonic lethality and severe defects in SMC investment of
vessels 135. In addition, neural crest cell-specific expression of a dominant negative MAML
that inhibits all Notch family members disrupted aortic arch development and reduced SMC
differentiation 136. The decrease in artery maturation observed in Notch3 deficient mice 137
and the requirement for Notch3 in EC-dependent mural cell differentiation 138 provide
additional evidence that Notch activation is important for SMC identity. Interestingly, a
mutation in Notch3 is causal for CADASIL (cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephaly), a neurovascular disorder associated with SMC
abnormalities 139.
A number of studies have demonstrated that expression of the NICD inhibited SMC
differentiation marker gene expression significantly complicating our understanding of this
pathway 140, 141. These inhibitory effects are due, at least in part, to up regulation of the
canonical Notch target genes of the HERP/HEY family which have been shown to inhibit
SMC differentiation marker gene expression by interfering with SRF/myocardin binding to
CArG elements and by directly inhibiting the function of the NICD/RBPJ complex 43, 142.
HERP1/HEY2 is up-regulated following vascular injury and HERP1/HEY2 knockout mice
have reduced neointimas suggesting that that this mechanism plays a role during SMC
phenotypic modulation 43, 143. Further supporting this idea, Notch3 deficient mice do not
develop pulmonary hypertension in response to hypoxia and knockdown of HES-5 in human
pulmonary artery SMC decreased proliferation and increased SMC differentiation marker
gene expression 144. Thus, in regard to the regulation of SMC differentiation, the eventual
outcome of Notch activation seems to depend upon the efficacy and timing of these
competing transcriptional events. Notch receptor and ligand expression levels are known to
change during development and following injury 145 and it will be important to determine
whether alterations in these parameters have significant effects on the dynamics of Notch
activation. It will also be critical to determine how the Notch pathway in SMC is influenced
by additional signaling and transcription mechanisms especially those that regulate
chromatin structure.
Inhibition of SMC differentiation by PDGF-BB
The growth factor, PDGF-BB, is a critical regulator of early vascular development. It is
highly expressed by EC and is required for the initial recruitment and subsequent
proliferation of pericytes and SMC within the maturing vasculature 146. However, treatment
of differentiated SMC with PDGF-BB strongly stimulates SMC phenotypic modulation by
enhancing SMC proliferation and migration and down-regulating SMC differentiation
marker gene expression (see 147 for review). The observations that PDGF-BB is released
upon vessel injury 148 and that inhibition of PDGF-BB signaling inhibits neointimal
growth 149 strongly suggest that it is a major regulator of SMC phenotype in vivo. It is clear
that PDGF-BB regulates SMC growth and differentiation by multiple, but partially
overlapping mechanisms. Activation of tyrosine kinase receptors such as PDGFRβ triggers
the Ras/Raf/MEK/ERK kinase cascade leading to Elk-1 phosphorylation and the SRF-
dependent up-regulation of multiple early response growth genes. Importantly, myocardin
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and Elk-1 bind to the same region of SRF and compete for SRF binding 150. Thus, in PDGF-
BB treated SMC, phosphorylated Elk-1 inhibited SMC differentiation marker gene by
displacing myocardin (and likely the MRTFs) from the SMC-specific promoters 150, 151.
ERK-dependent phosphorylation of MRTF-A at Ser454 was also shown to inhibit MRTF-A
nuclear accumulation in HeLa cells 152. Results from the Owens laboratory suggest that the
negative effects of PDGF-BB are at least partially mediated by the pluripotency
transcription factor, KLF4. These authors demonstrated that KLF4was strongly induced by
PDGF-BB and vascular injury, and inhibited SMC differentiation marker gene expression
by decreasing myocardin expression, interfering with SRF/myocardin factor binding to the
SMC-specific promoters, and modulating the chromatin environment near the SMC-specific
promoters 14, 153, 154. Although this group has also identified a G/C repressor within the
SM22 promoter that is required for its down-regulation upon injury or treatment with
PDGF-BB 155, 156, it is somewhat unclear whether the inhibitory effects of KLF4 are
mediated by this cis element.
Integrin-matrix signaling
Early studies demonstrated that SMC differentiation during development correlated strongly
with a change in basement membrane composition from fibronectin, which supports SMC
proliferation, to collagen IV and laminin, which promote SMC differentiation 157–159.
Matrix degradation and the re-expression of fibronectin and other growth promoting matrix
components such as collagen I also occur following vessel injury and likely contribute to
SMC phenotypic modulation 160. Matrix components signal through heterodimeric integrin
receptors composed of α and β subunits and the mechanisms by which integrins regulate cell
growth are fairly well described (see 161 for review). In brief, integrin activation leads to the
formation of multiprotein focal adhesion signaling complexes and the activation of the non-
receptor tyrosine kinases, FAK and c-src. Tyrosine phosphorylation of FAK, Shc, and other
focal adhesion scaffolding proteins such paxillin a p130Cas, leads to activation of the Raf/
Ras/MEK/ERK kinase cascade through Grb2/Sos-dependent mechanisms. As discussed
above, up- or down-regulation of ERK signaling may explain the effects of integrin-matrix
signaling on SMC differentiation marker gene expression, but other mechanisms are likely
to be involved. Orr et al recently demonstrated that plating SMC on collagen IV, but not on
collagen I, enhanced myocardin expression, although the mechanism for this effect was not
clear 162. Integrin signaling is also a major regulator of the actin cytoskeleton and is required
for a cell’s ability to sense and respond to mechanical forces (see 163 for review). Although
the effects of these cues on SMC-specific gene expression are mediated, at least in part, by
RhoA/MRTF-dependent mechanisms 76, 80, 164, 165, the signaling pathways by which
integrins, FAK, and mechanical forces regulate RhoA in cells are only partially
understood 166. Interestingly, Kogata et al have shown that integrin-linked kinase (ILK), a
very weak serine/threonine kinase that interacts with the β1 integrin receptor, negatively
regulates RhoA activity in SMC and that deletion of ILK in PDGFRβ expressing cells in
vivo resulted in defects in SMC investment and hypercontractility 167. Although Wu, et al
have demonstrated that ILK negatively regulates SMC differentiation marker gene
expression 168, additional studies will be required to confirm that these effects were due to
alterations in RhoA signaling.
Interestingly, several SMC-selective integrin and/or signaling molecules have been
described that regulate SMC differentiation marker gene expression. First, in close
collaboration with the Taylor lab, we have shown that FAK activity in SMC is regulated by
a dominant negative FAK variant termed FRNK (FAK-related non-kinase) that is selectively
expressed in large arteries 169. FRNK expression is up-regulated during early post-natal
development and following vascular injury when SMC are transitioning from the
proliferative to contractile phenotype, and FRNK promotes this transition by inhibiting SMC
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growth and migration and by stimulating SMC differentiation marker gene
expression 170, 171. In a second collaborative effort with the Taylor lab, we demonstrated
that the SMC-selective LIM protein, leupaxin, interacts with SRF to activate SMC-specific
gene expression most likely by scaffolding additional transcription co-activators through its
multiple LIM domains 172. Importantly, leupaxin localizes to focal adhesions and the
nucleus, and we demonstrated that nuclear translocation of leupaxin was inhibited by plating
cells on fibronectin or by expression of an active FAK variant. Chang et al demonstrated
that the SMC-specific LIM proteins, CRP1 and CRP2 enhanced SMC-specific gene
expression by facilitating SRFs interaction with Gata–6 173. The CRPs have been shown to
bind α-actinin and to localize to actin stress fibers within the cytoplasm 174. Whether CRP
nuclear/cytoplasmic shuttling is regulated by integrin-matrix signaling is unclear but seems
likely. The four and a half LIM domain-containing protein, FHL2, is a CArG-dependent
cardiac/SMC-selective protein that also interacts with SRF 175. In contrast to the effects of
leupaxin and the CRPs, FHL2 was shown to inhibit SMC-specific transcription by
competitively interfering with MRTF binding to SRF. Like leupaxin, FHL2 localizes to
focal adhesions and its nuclear accumulation was enhanced by activation of RhoA 176
suggesting that FHL2 may act as a feedback inhibitor of RhoA/SRF-dependent gene
expression.
Summary and Unanswered Questions
The discovery of the myocardin factors has provided a regulatory framework for our
understanding of the control of SMC phenotype. Figures 1 summarizes many of the
signaling mechanisms that stimulate and/or maintain SMC differentiation while figure 2
summarizes those that promote SMC phenotypic modulation. It is important to emphasize
that significant cross-talk exists between these signaling mechanisms and that SMC
phenotype likely reflects the integrated sum of these pathways. It is clear that many
important questions still remain. What are the epigenetic mechanisms that allow
transcription factor access to the SMC-specific genes? What are the mechanisms that
regulate myocardin factor expression? To what extent does RhoA-dependent MRTF nuclear
localization regulate SMC differentiation in vivo? How do the direct and indirect actions of
Notch affect SMC differentiation? Can we define the cis regulatory elements and trans-
acting factors that mediate Smad interactions with the SMC-specific promoters. What are
the mechansims by which integrin-matrix signaling regulate RhoA and the localization of
the LIM protein SRF co-factors in SMC? Do signaling pathways have differential effects on
SMC phenotype based upon developmental origin? Can we identify novel signaling targets
for the treatment of cardiovascular diseases that involve SMC phenotypic modulation? The
recent development of tools for studying signaling, transcription, and chromatin networks on
a genome-wide basis will certainly facilitate these efforts and will hopefully increase our
understanding of the complex signaling and transcription mechanisms that regulate SMC
differentiation.
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Figure 1. Signaling pathways that stimulate and/or maintain SMC differentiation
The red arrows denote nuclear translocation events.
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Figure 2. Signaling pathways that promote the phenotypic modulation of SMC
Note that myocardin levels are significantly reduced. The red arrows denote nuclear
translocation events.
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